Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France.

Systemic sclerosis interstitial lung disease quality of life

Journal

Journal of scleroderma and related disorders
ISSN: 2397-1991
Titre abrégé: J Scleroderma Relat Disord
Pays: England
ID NLM: 101685427

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 07 01 2021
accepted: 03 04 2021
entrez: 7 4 2022
pubmed: 8 4 2022
medline: 8 4 2022
Statut: ppublish

Résumé

The objectives of this study were to describe the impact of systemic sclerosis associated interstitial lung disease, on quality of life, to estimate the correlation between quality of life and severity of lung disease and to assess the impact of interstitial lung disease on caregivers. Seven investigators included systemic sclerosis associated interstitial lung disease patients from December 2019 to April 2020. Sociodemographics and clinical data were collected. Patients reported outcomes and questionnaires were used with 1 generic patients reported outcome (EQ-5D-5L), 1 specific PRO (Brief Interstitial Lung Disease) and 2 self-reported questionnaires on impact of SSc complications and impact on caregivers. The correlation between forced vital capacity and EQ-5D-5L score was estimated with a multivariate linear regression model adjusted on several covariates. In all, 89 patients were included. 26.4% were males, mean age was 58.2 ± 14.5 years. Mean EQ-5D-5L score = 0.79 ± 0.22 (median = 0.85). Mean EQ-5D-5L visual analog scale score = 60.8 ± 20.4 (median = 61.5). Mean King's Brief Interstitial Lung Disease score = 58.4 ± 12.7 (median = 58.0). After adjustment on covariates, a significant correlation between forced vital capacity and EQ-5D-5L score was found with an increase of 0.003 of the EQ-5D-5L score for a 1% increase of FVC (p = 0.0096). No significant correlation between forced vital capacity and the EQ-VAS and King's Brief Interstitial Lung Disease score were found. The impact of SSc on other organs was significantly correlated with EQ- 5D-5L score, respectively, for the impact scores on the lung system (p = 0.0003), heart system (p = 0.0182), Raynaud's syndrome (p = 0.0015), digestive system (p = 0.0032), joints/muscles (p = 0.0003), skin (p < 0.0001), kidney (p = 0.0052) and gastro-oesophageal reflux (p = 0.0063). Significant correlations between King's Brief Interstitial Lung Disease score and lung system (p < 0.0001), heart system (p < 0.0001), digital ulcers (p = 0.058), digestive system (p < 0.0001), kidney (p = 0.0004), skin (p = 0.0499) and gastro-oesophageal reflux (p = 0.0033) scores were found 68.5% of patients reported their need for a caregiver to help them in their daily life activities. Our study highlighted the strong burden of systemic sclerosis associated interstitial lung disease` for patients, especially with an impact on quality of life, on other organs manifestations and need for caregivers in their daily life.

Identifiants

pubmed: 35386942
doi: 10.1177/23971983211013979
pii: 10.1177_23971983211013979
pmc: PMC8922678
doi:

Types de publication

Journal Article

Langues

eng

Pagination

49-56

Informations de copyright

© The Author(s) 2021.

Déclaration de conflit d'intérêts

Declaration of conflicting interests: The Editor/ Editorial Board Member of JSRD is an author of this paper, therefore, the peer review process was managed by alternative members of the Board and the submitting Editor/Board member had no involvement in the decision-making process. Disclosure: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for the development of the manuscript. Writing, editorial support, and formatting assistance was provided by Stéphane Bouée, MD, of CEMKA, which was contracted and funded by BI. BI was given the opportunity to review the manuscript for medical and scientific accuracy.

Références

Am J Epidemiol. 2004 Jun 15;159(12):1140-9
pubmed: 15191931
Pharmacoeconomics. 2020 Apr;38(4):413-425
pubmed: 31912325
BMJ Open Respir Res. 2020 Jun;7(1):
pubmed: 32576559
Arthritis Rheum. 2003 Oct 15;49(5):689-96
pubmed: 14558055
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
J Rheumatol. 2019 Sep;46(9):1103-1108
pubmed: 30824634
Ann Rheum Dis. 2007 Jun;66(6):754-63
pubmed: 17234652
J Scleroderma Relat Disord. 2020 Mar;5(2 Suppl):48-60
pubmed: 32455167
Reumatismo. 2019 Jul 09;71(2):62-67
pubmed: 31309775
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Arthritis Rheum. 2009 Aug 15;61(8):1112-20
pubmed: 19644906
J Scleroderma Relat Disord. 2016 May-Aug;1(2):177-240
pubmed: 29242839
Br J Clin Psychol. 2002 Jun;41(Pt 2):157-74
pubmed: 12034003
Lancet Respir Med. 2020 Mar;8(3):304-320
pubmed: 32113575
Trends Cardiovasc Med. 2021 Feb;31(2):93-98
pubmed: 31932098
Musculoskeletal Care. 2012 Mar;10(1):18-28
pubmed: 22076953
Joint Bone Spine. 2021 Mar;88(2):105081
pubmed: 32992030
Thorax. 2012 Sep;67(9):804-10
pubmed: 22555278
Arthritis Res Ther. 2020 Oct 28;22(1):257
pubmed: 33115544
Exp Ther Med. 2020 Mar;19(3):1739-1746
pubmed: 32104228
Arthritis Rheum. 2009 Aug 15;61(8):1054-61
pubmed: 19644904
Autoimmun Rev. 2010 Mar;9(5):A311-8
pubmed: 19906362
PLoS One. 2016 Oct 5;11(10):e0163894
pubmed: 27706206
Semin Arthritis Rheum. 2016 Aug;46(1):115-23
pubmed: 27132536
Best Pract Res Clin Rheumatol. 2010 Dec;24(6):857-69
pubmed: 21665131
Scand J Rheumatol. 2015 May;44(3):238-46
pubmed: 25521915
Respir Investig. 2021 Mar;59(2):252-259
pubmed: 33223487
Arthritis Res Ther. 2019 Feb 15;21(1):61
pubmed: 30770765
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Ann Rheum Dis. 2017 Nov;76(11):1897-1905
pubmed: 28835464
Rheumatology (Oxford). 2004 Sep;43(9):1129-37
pubmed: 15213329
Arthritis Rheum. 2013 Aug;65(8):1953-62
pubmed: 23666787
Clin Rheumatol. 2020 May;39(5):1543-1549
pubmed: 31980971
Mod Rheumatol. 2020 Jul;30(4):681-686
pubmed: 31269847
Arthritis Rheumatol. 2020 Mar;72(3):465-476
pubmed: 31682743

Auteurs

Yannick Allanore (Y)

Rheumatology, Cochin Hospital, Université de Paris, Paris, France.

Joel Constans (J)

Vascular Medicine, CHU Bordeaux, Bordeaux, France.

Dominique Godard (D)

Association des Sclerodermiques de France, Baccon, France.

Gerard de Pouvourville (G)

ESSEC Business School, Cergy Pontoise, France.

Stephane Bouee (S)

Real World Evidence, CEMKA, Bourg La Reine, France.

Viviane Jeanbat (V)

Real World Evidence, CEMKA, Bourg La Reine, France.

Clement Teissier (C)

Real World Evidence, CEMKA, Bourg La Reine, France.

Katell Le Lay (K)

Boehringer Ingelheim, Paris, France.

Julien Chollet (J)

Boehringer Ingelheim, Paris, France.

Eric Hachulla (E)

Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.

Classifications MeSH